Teva expands work on women's health; Evotec AG collaborates with Yale;

 @FierceBiotech: Buyout buzz: Biopharma players staying focused on bolt-on deals. Report | Follow @FierceBiotech

@JohnCFierce: Medicines Co. spikes after anti-clotting drug impresses in second run at PhIII. Story | Follow @JohnCFierce

> Teva Pharmaceuticals ($TEVA) says it plans to boost its work on women's health beyond fertility. Story

> Germany's Evotec AG says it will collaborate with investigators at Yale in the search for new drugs that target metabolic diseases, CNS, immunological diseases and cancer. Release

> GlaxoSmithKline ($GSK) and Theravance ($THRX) have filed the LAMA/LABA combo UMEC/VI for approval in Europe. Story

> Onconova Therapeutics has struck a discovery deal with GVK BIO, an Indian CRO, in the hunt for new cancer drugs. Release

Medical Device News

 @FierceMedDev: Samsung med device sales spike in 2012. Item | Follow @FierceMedDev

@MarkHFierce: Abbott is beginning a bioresorbable stent trial in the U.S. Big news for the company and its stent rivals alike. More | Follow @MarkHFierce

 @DamianFierce: $LIFE is teaming up with Boston Children's Hospital to develop genomics-based diagnostics. News | Follow @DamianFierce

> LabCorp inks companion diagnostic deal with Verastem. News

> JPM: U.S., EU regulators to consider GE's Alzheimer's imaging agent. Story

Pharma News

@FiercePharma: Will Bausch + Lomb choose IPO over a sale to pharma? Related Q: Can Warburg Pincus get its $10B+ asking price? More | Follow @FiercePharma

@EricPFierce: COO Perez says Cubist well positioned in new hospital-centric payer world. "The world has turned and we are Cinderella now." | Follow @EricPFierce

 @AlisonBFierce: Altravax landed $1.2M from NIAID to advance its dengue vaccine and hepatitis therapeutic. More | Follow @AlisonBFierce

> AbbVie CFO sees no need for big acquisition. Report

> Swiss insurer jumps into legal fight over Bayer's Yasmin. News

> Teva CEO says job cuts are small part of efficiency plans. Story

Drug Delivery News

> Alnylam prepares for U.K. Phase I and plans for the future. Article

> Agile snags $15M loan to push pipeline products forward. News

> FDA approves EMD Serono-Pfizer's Rebif auto-injector. Item

> FDA grants orphan label to eye cancer chemo-delivery combo. Story

Biomarkers News

> Biomarkers could tag chemo heart risk. Item

> Stem cell factor could improve ovarian cancer prognosis. Article

> Crescendo Bioscience deploys $28M Series D to market RA Dx biomarker test. News

> New target could improve treatment of deadly pancreatic cancer. Story

And Finally… A new poll summary finds strong public support for federally assisted biomedical research. Release

 

 

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.